|
|
Biotech
|
|
||
Re: snips$MGTA Magenta intends to complete enrollment in Phase 2 in 2020 and continue dialogue with the FDA under the RMAT designation on design of a registration-enabling study, and to have discussions with the European Medicines Agency for development in Europe as well – $MGTA (+3.0% pre) Magenta Therapeutics (MGTA) Reports Updated Phase 2 Data on MGTA-456 Cell Therapy $VTGN VistaGen Announces Positive Results of Newly Published Exploratory Phase 2a Study of PH10 for Rapid-Onset Treatment of Major Depressive Disorder Aptose Biosciences Inc. $APTO - $8.60 - Buy - $16.00 PT): What's the Value of Aptose After Arqule Goes to Merck? Initiating Coverage with a Buy Rating and $16 PT (Analyst: Jason McCarthy, Ph.D.) $CYCN lots of new eyes now. Key slide from JPM presentation last month: Partnering of praliciguat for ph3 in DN a top priority (mentioned progress expected early 2020), ph2 SCD data expected mid year, launch of CNS program into high value/orphan CNS diseases this year: $BLU BELLUS Health to Present at Two Upcoming Healthcare Investor Conferences:SVB Leerink Conference 02/27 at 10:00 am EST,Cowen Conference 03/3 at 8:00 am EST |
return to message board, top of board |